Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study.
Hamilton F. et al, (2024), Lancet Microbe
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates.
Arunachalam PS. et al, (2024), Sci Transl Med, 16
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ Vaccines, 9
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
Mentzer AJ. et al, (2024), Nat Med, 30, 1384 - 1394
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), Lancet Infect Dis, 24, 465 - 475
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture
Lv X. et al, (2024), iScience, 27
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS. et al, (2024), Lancet, 403, 533 - 544
Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture.
Schurz H. et al, (2024), Elife, 13
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.
Chong AY. et al, (2024), Am J Hum Genet
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Reinke S. et al, (2023), Cell Rep Med
Mexican Biobank advances population and medical genomics of diverse ancestries.
Sohail M. et al, (2023), Nature
Injectable core-shell microspheres deliver prime-boost immunisation in a single shot
Guyon R. et al, (2023)
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D. et al, (2023), Lancet Infect Dis, 23, 956 - 964
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.
Dold C. et al, (2023), Sci Transl Med, 15
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Li K. et al, (2023), Front Immunol, 14
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome Open Res, 8